The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2021 Developments in RCC & UC: Pembro for ccRCC, Sacituzumab Govitecan for mUC, Enfortumab Vedotin for Advanced UC, Bladder Sparing Treatment

63 views
July 22, 2021
Comments 0
Login to view comments. Click here to Login